Building a healthcare board that actually helps

What most boards do wrong

The default startup board — three investors, two founders, one independent — is optimized for oversight, not counsel. In healthcare, where regulatory, clinical, and payer dynamics dominate, this is often the wrong configuration.

A better default

Reserve at least one independent seat for a senior operator with deep domain experience — a former CMO of a health system, a payer executive, or an experienced regulatory leader. This one seat can materially change outcomes.

The board meeting itself

Ship the deck 72 hours in advance. Spend meeting time on the top three open questions, not on the historical numbers. Rotate the specific topics deep-dived each quarter.

What to protect

Founder time, decision speed, and honesty. A board that erodes any of these is a board that will hurt the company, however well-intentioned.

The default board is built for the wrong job

Most healthcare boards inherit a generic venture governance template — quarterly updates, a compliance checklist, a handful of observer seats — that was designed to catch problems, not to help solve them. That template makes sense for a company whose main risk is financial mismanagement, but healthcare startups more often fail on clinical validation, regulatory sequencing, and payer access, none of which a standard governance cadence surfaces early enough to act on.

The result is a board that finds out about a clinical or regulatory problem the same quarter it becomes a crisis, rather than the two quarters earlier when it was still a manageable risk.

A better default composition

We push founders toward at least one board seat or standing advisor role held by someone with recent operating experience inside a payer or health system, not just venture and clinical-academic backgrounds. That perspective catches commercial and access risks the rest of the board structurally cannot see, and it changes the quality of strategic debate in the room noticeably.

Redesigning the meeting itself

The single highest-leverage change is spending less board time on historical metrics review and more on forward decision-forcing questions — the two or three choices the company actually needs help making in the next quarter. Boards that pre-read financials and spend live time on decisions consistently produce better founder outcomes than boards that spend the meeting walking through the deck.

What founders should protect regardless

Founders should protect their right to bring a problem to the board before it is solved, not just to report on how it was solved. A board culture that punishes early disclosure of bad news trains founders to hide problems until they are unmanageable, which is precisely the failure mode a good board composition is supposed to prevent.

How to onboard a new board member well

New board members, even excellent ones, often spend their first two quarters re-litigating decisions the company already made, simply because nobody gave them the context behind those decisions upfront. A structured onboarding packet covering the company's clinical evidence strategy, regulatory posture, and prior strategic pivots saves real time and prevents a new voice from accidentally dragging the board backward into settled debates.

When to add a seat versus an advisor

Founders often default to adding a formal board seat when what they actually need is a standing advisor with a narrower, renewable commitment. A board seat is hard to unwind if the fit turns out to be wrong, while an advisory arrangement lets a founder test the working relationship before making it permanent, which matters more in healthcare than in most sectors given how specialized the useful expertise usually is.